Aratana Reports Filing For Product License For AT-014 In U.S. - Quick Facts

(RTTNews) - Aratana Therapeutics, Inc. (PETX) announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (ADXS) for the treatment of canine osteosarcoma and other cancers. The company expects that responses from the USDA to the filing will occur over the next 12 to 18 months.

The filing was submitted by Aratana Therapeutics, Inc. (PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize AT-014 (ADXS-cHER2 ) in animals.

ADXS-cHER2 is an investigational Lm-LLO cancer immunotherapy designed to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including canine and human bone cancer and breast cancer. Due to the data in canine osteosarcoma and the parallel the disease shares with human osteosarcoma, Advaxis is currently pursuing a clinical program with ADXS-cHER2 in osteosarcoma, which has been granted orphan drug designation by the U.S. Food and Drug Administration.